To the Editor: The findings of Yee et al. (July 14 issue)1 accord with our recent data, which also suggest a correlation between trough concentrations of cyclosporine in plasma and the manifestations of graft-versus-host disease (GVHD) after bone marrow transplantation. During the past five years, 65 patients (17 with acute lymphoblastic leukemia, 15 with acute nonlymphoblastic leukemia, 18 with chronic myelogenous leukemia, 12 with severe aplastic anemia, and 3 with neuroblastoma, stage IV; median age, 23 — range, 2 to 48) received cyclosporine to prevent GVHD. Bone marrow was obtained from HLA-identical, mixed leukocyte culture–negative siblings. All patients received cyclosporine.
ASJC Scopus subject areas